A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
← catalyst calendarNCT07213830 · readout in 2,156 d
Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
102estimated
Sites
11
Countries
Canada, France, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-06 | actual | When the study began enrolling |
| Primary completion | 2032-07-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-07-14 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
Intervention
- Biological: IPN01203
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants with dose limiting toxicity (DLT)
measured Within 28 days of first dose
Percentage of participants experiencing treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TE-SAEs).
measured From the first IPN01203 administration to 90 days after the last dose.
Phase Ib: Objective Response Rate (ORR)
measured At end of study (up to approximately 3 years)
Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed